Awakn Announces Shareholder Approval of Arrangement
TORONTO, CANADA, April 23 2025 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”), is pleased to announce that further to its press releases…
---
Investor Relations
About Awakn
Awakn is a Clinical Stage Biotechnology Company Developing Therapeutics for Substance Use and Mental Health Disorders.
Awakn has a near-term focus on Alcohol Use Disorder (AUD), a condition affecting approximately 29[¹] million adults in the US and approximately 40 million [²,³,⁴,⁵,⁶] in the US and key European for which the current standard of care is inadequate.
Our goal is to provide breakthrough therapeutics to addiction sufferers in desperate need and our strategy is focused on commercialising our R&D pipeline across multiple channels.
Awakn Life Sciences Corp. Stock Price (NEO) Information provided by Stockdio.
Awakn Life Sciences Corp. (AWKN.NE)
Awakn corporate information
Download latest Awakn Corporate Presentation and visit Awakn Financials Info on Sedar.
Awakn Corporate Governance
Download latest Awakn Corporate Governance documents.
Analyst Coverage
FIRM
Stifel
Maxim Group LLC
ANALYST
Andrew Partheniou
Jason McCarthy
News
Awakn Provides Supplemental Disclosure in Connection with Proposed Plan of Arrangement
TORONTO, CANADA, April 11, 2025 – Further to its press release dated February 27, 2025 and its management information circular dated May 10, 2025 (the “Circular”), Awakn Life Sciences Corp….
Awakn Enters into Arrangement Agreement for the Acquisition of Awakn by Solvonis Therapeutics plc
TORONTO, CANADA, February 27, 2025 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing therapeutics for substance use and mental…
Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD
Toronto, Canada – January 28, 2025 – Awakn Life Sciences Corp. (CSE: AWKN, OTCPink: AWKNF, FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics for…
Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder
Toronto, Canada – January 20, 2025 – Awakn Life Sciences Corp. (CSE: AWKN, OTCPIN: AWKNF, FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use…
Awakn Enters Into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) plc
TORONTO, CANADA, December 16, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”) a clinical-stage biotechnology company developing therapeutics for substance use and mental…
Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program
Toronto, Canada – December 11, 2024 – Awakn Life Sciences Corp. (CSE: AWKN, OTCQB: AWKNF, FSE: 954) (“Awakn” or the “Company”), a clinical-stage biotechnology company developing therapeutics for substance use…
Enquiries
Investor relations:
Anthony Tennyson
CEO, Awakn Life Sciences
anthony.tennyson@awaknlifesciences.com
Media enquiries:
Gordo Whittaker,
CMO, Awakn Life Sciences
gordo@awaknlifesciences.com
References:
1. US Substance Abuse and Mental Health Services (SAMHSA), 2022 National Survey on Drug Use and Health
2. UK The National Institute for Health and Care Excellence (NICE) - Alcohol-use disorders diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence
3. Jahrbuch Sucht 2020 der Deutschen Hauptstelle für Suchtfragen
4. Inserm. Reducing the harm associated with alcohol consumption. Summary and recommendations. Collection Expertise collective. Montrouge: EDP Sciences, 2022.
5. Istituto Superiore di Sanità EpiCentro
6. Monografía. Alcohol 2021: Consumo y Consecuencias
Sign Up for Newsletter
MAIN OFFICE
Awakn Life Sciences Corp
301-217 Queen St. W
Toronto, Ontario M5V 0R2
Canada
© 2023 Awakn Life Sciences Corp | Privacy Policy | Disclaimer
// ABOUT US SUB NAV
// THERAPEUTIC FOCUS SUB NAV
// R&D SUB NAV
